Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) Trial

Journal of the American College of Cardiology

Volumn 55, Issue 12, 2010, Pages 1266-1273

  Ridker, Paul M ^a   MacFadyen, Jean ^a   Cressman, Michael ^b   Glynn, Robert J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

chronic kidney disease; CRP; statins; trial

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN;

AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART DEATH; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYOPATHY; NEOPLASM; PAIN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVASCULARIZATION; RHABDOMYOLYSIS; RIGIDITY; RISK REDUCTION; SIDE EFFECT; STROKE; UNSTABLE ANGINA PECTORIS;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRIMARY PREVENTION; PYRIMIDINES; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 77949332406     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.01.020     Document Type: Article

References (16)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
2. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
3. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003) 2154-2169
4. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
5. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407
6. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
7. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
8. Glynn R.J., Danielson E., Fonseca F.A., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360 (2009) 1851-1861
9. Altman D.G., and Andersen P.K. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319 (1999) 1492-1495
10. Ridker P.M., Danielson E., Fonseca F.A., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 (2009) 1175-1182
11. Brosius III F.C., Hostetter T.H., Kelepouris E., et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 114 (2006) 1083-1087
12. Shepherd J., Kastelein J.J., Bittner V., et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 51 (2008) 1448-1454
13. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
14. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
15. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114 (2006) 281-288
16. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E., and The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (1999) 230-235